Highlights Exelixis, Inc.

Equities

EXEL

US30161Q1040

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-03 pm EDT			5-day change	1st Jan Change
21.93 ^USD	+1.08%		+6.61%	-8.59%

May. 31	Exelixis Insider Bought Shares Worth $8,733,955, According to a Recent SEC Filing	MT
May. 20	Exelixis Settles Cabometyx Patent Litigation with Cipla	MT

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Exelixis Settles Cabometyx Patent Litigation with Cipla	May. 20	MT
Exelixis Files Patent Complaint Against Cipla's Cancer Treatment	May. 10	DJ
Exelixis Q1 Non-GAAP Earnings, Revenue Rise; 2024 Revenue Guidance Maintained -- Shares Fall After Hours	Apr. 30	MT
Exelixis Guides For 2024 Revenue of $1.825-$1.925 Billion, vs CIQ Analyst Consensus of $1.91 Billion	Apr. 30	MT
Earnings Flash (EXEL) EXELIXIS Reports Q1 Revenue $425.2M, vs. Street Est of $460.5M	Apr. 30	MT
Earnings Flash (EXEL) EXELIXIS Reports Q1 EPS $0.17, vs. Street Est of $0.29	Apr. 30	MT
Tranche Update on Exelixis, Inc.'s Equity Buyback Plan announced on January 8, 2024.	Apr. 30	CI
Exelixis, Inc. Reaffirms Earnings Guidance for the Year 2024	Apr. 30	CI
Exelixis, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 30	CI
Exelixis Swings to Earnings in Fiscal Q4 as Sales Increase; 2024 Revenue Guidance Set	Feb. 06	MT
Exelixis, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 06	CI
Exelixis, Inc. Provides Earnings Guidance for the for Fiscal Year 2024	Feb. 06	CI
Earnings Flash (EXEL) EXELIXIS Reports Q4 Revenue $480M, vs. Street Est of $477.9M	Feb. 06	MT
Earnings Flash (EXEL) EXELIXIS Posts Q4 EPS $0.33, vs. Street Est of $0.31	Feb. 06	MT
Exelixis, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 06	CI
Exelixis, Inc. Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024	Jan. 25	CI
Bristol Myers Squibb and Exelixis, Inc. Announce Four-Year Follow-Up Results from the CheckMate -9ER Trial Evaluating Opdivo (cabozantinib)	Jan. 22	CI
Exelixis Sees Fiscal 2023 Revenue at Lower End of Guidance; Issues Fiscal 2024 Revenue Outlook	Jan. 08	MT
Tranche Update on Exelixis, Inc.'s Equity Buyback Plan announced on March 20, 2023.	Jan. 08	CI
Exelixis, Inc. announces an Equity Buyback for $450 million worth of its shares.	Jan. 08	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Exelixis, Inc.

Equities

EXEL

US30161Q1040

Highlights

Filters